World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)

Description:

The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. It's a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing.

The field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded. This report, The Worldwide Market for Prescription Dermatological Drugs represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.

The driving forces for this market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.

The worldwide market for prescription dermatology drugs includes products in the following categories:
- Prescription Acne and Rosacea Drugs
- Prescription Antiaging and Photodamage Drugs
- Prescription Dermatitis and Seborrhea Drugs
- Prescription Fungal Infection Drugs
- Prescription Hair Loss and Hair Removal Drugs
- Prescription Hyperpigmentation/Melasma Drugs
- Prescription Psoriasis Drugs
- Prescription Skin Cancer Drugs
- Other Prescription Skin Disorder Drugs

This report details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.

The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry over the forecast period. The worldwide pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come. The sector is ripe for the picking, too, with the financial crisis having created an impressive buyer's market for larger companies, as smaller firms struggle to extend financing. True globalization of pharmaceuticals has arrived. Most of the growth in the next few years will be outside the US, Europe and Japan. It's a very dynamic time for the industry focusing on a worldwide market.

The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 30 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
All market data pertains to the worldwide market at the manufacturers' level. Data are expressed in current U.S. dollars. The base year for data was 2015. Historical data are provided for each of the years 2013 to 2014, and forecast data are provided for each of the years 2015 through 2020. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2015 base year.

The following companies are profiled in this report:

Allergan Inc.
Allergan Inamed Corporation
Barrier Therapeutics, Inc
Bayer AG
PharmaDerm Pharmaceuticals, Inc
Bristol-Myers Squibb
Collagenex (now Galderma) Pharmaceuticals
Galderma S.A.
Genentech, Inc.
GlaxoSmithKline Plc
Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
Medicis Pharmaceutical Corporation
Merck & Company, Inc.
Mylan Pharmaceuticals, Inc,
Novartis Pharmaceuticals Corporation
Nycomed Inc.
Pfizer, Inc.
Q-Med AB
Roche Group (F. Hoffmann-La Roche Ltd.)
Schering (now Merck)-Plough Corporation
Sinclair Pharma Plc.
SkinMedica
Stiefel Laboratories, Inc.
Valeant Pharmaceuticals, Inc.

Contents:

CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Competitor Analysis
CHAPTER TWO: INTRODUCTION
Structure and Function of the Skin
Epidermis
Dermis
Subcutaneous Tissue
Epidermal Appendages
Functions of the Skin
Effects of Aging on the Skin
Dermatological Conditions and Treatment
Pharmacokinetics
Drug Absorption
Distribution
Bioavailability
Drug Delivery Methods
Demographics of Skin Disorders, Incidence, and Prevalence
CHAPTER THREE: ISSUES AND TRENDS
Patient Compliance
Cosmetic Dermatologists
Sunscreen Use
Melanoma Survival Rates Falter
Indoor Tanning Issue
Phosphatidylglycerol and Psoriasis
New Filler Options
Consumer Confusion
Genetic Link to Psoriasis
Biologic Dermatology
Rx-to-OTC Switches
Cosmeceuticals
Antioxidants
Polypeptides
Teledermatology
Reimbursement Issues
Market Shift Towards less invasive Procedures
Medi-Spas
Combination therapies Thrive
Competitive, Economic, Social Forces Driving Market Demand
Society's Obsession with Physical Appearance
Regulatory Influences: US & International
International Authorities
U.S. FDA & Other Regulatory Agencies
Effects of Health Insurance Programs & Treatment Costs
Competitive Influences—Impact on Market & Treatment Modalities
Facial Skin--Bio-Physiology
The “Gray Areas” of Medicine
Laser Therapy
Narrowband Ultraviolet B
Photodynamic Therapy
PYCR1 Gene
Changes in Credit Card Terms
Patient Protection and Affordable Care Act
Thermage
BRAF Gene
New Oral Medications and Research for Acne
Synthetic Lipids for Skin Healing
Importance of Drug Delivery
Industry Consolidation
CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS .69
Description of Disorders
Description of Products
Benzoyl Peroxide
Current Suppliers
Retinoids
Topical Formulations
All-trans Retinoic Acid (Tretinoin)
Adapalene
Tazarotene
Systemic Formulations
Isotretinoin
Current Suppliers
Antibiotics
Description of Products
Azelaic Acid
Clindamycin
Erythromycin
Metronidazole
Sodium Sulfacetamide
Others
Current Suppliers
Oral Contraceptives
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS

Overview
Description of Products
Keratolytics
Moisturizers
Retinoids
Sunscreens
Botox and Fillers
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS

Overview
Description of Products
Topical Corticosteroids
Systemic Corticosteroids
Other Products
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS

Overview
Description of Products
Systemic Formulations
Terbinafine
Itraconazole
Fluconazole
Griseofulvin
Ketoconazole
Echinocandin
Current Suppliers
Topical Formulations
Polyenes
Azoles
Miconazole
Clotrimazole
Ketoconazole
Oxiconazole
Econazole
Sulconazole
Allylamines and Benzylamines
Naftifine
Terbinafine
Butenafine
Other Topical Formulations
Novel Products
Current Suppliers
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis

CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS

Overview
Description of Products
Antiandrogens
Androgen Inhibitors
Other Treatments
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis

CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS

Overview
Description of Products
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS

Overview
Description of Products
Selected Topical Psoriasis Products
Anthralin
Coal Tar
Methoxsalen
Second-generation Retinoids
Tazarotene
Topical Vitamin D
Vitamin D Analogs
Vanos
Veticical Ointment
Selected Systemic Psoriasis Preparations
Betamethasone
Cortisone Acetate
Cyclosporine
Hydrocortisone
Methotrexate
Olopatadine Hydrochloride
Tacrolimus
Light Therapy
Biologics
Novel Products
Research and Development
Market Size and Growth
Worldwide Market by Type
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Future of the Market
Competitive Analysis

CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS

Overview
Nonmelanoma Skin Cancers
Actinic Keratoses
Basal Cell Carcinoma
Squamous Cell Carcinoma
Cutaneous T-cell Lymphoma
Dysplastic Nevus Syndrome
Malignant Melanoma
Description of Products
5-Fluorouracil
Mechlorethamine/Nitrogen Mustard
Carmustine/BCNU (Topical)
Vinblastine (Intralesional) and Others
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS
Overview
Antivirals
Antiparasitics
Description of Products
Antivirals
Antiviral Drugs
Immunoenhancing Drugs
Current Suppliers
Antiparasitic Agents
Current Suppliers
Other Skin Related Products
Research and Development
Market Size and Growth
Worldwide Market
Markets by Geographical Region
United States
Europe
Japan
Rest of World
The Future of the Market
Competitive Analysis
CHAPTER THIRTEEN: WORLD MARKET SUMMARY
Overview
Total Market Size and Forecast
Market Analysis by Country
United States
Europe
Japan
Rest of World
Market and Competitive Analysis
CHAPTER FOURTEEN: CORPORATE PROFILES
AbbVie, Inc.
Allergan
Amgen, Inc.
Anacor Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Bayer AG
Bristol-Myers Squibb
Galderma S.A.
Genentech, Inc.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Company, Inc.
Mylan N.V
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
PharmaDerm
Stiefel
Sinclair IS Pharma Plc.
Stratus Pharmaceuticals, Inc.
Valeant Pharmaceuticals International
APPENDIX
LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1
The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and 2020
Figure 1-1
The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and 2020
CHAPTER TWO: INTRODUCTION
   Table 2-1
   Common Bases for Topical Dermatological Medications
   Table 2-2
Worldwide Incidence and Prevalence of Selected Dermatologic Conditions
CHAPTER THREE: ISSUES AND TRENDS
   Table 3-1
   Selected Dermatological Rx-to-OTC Switches
   Table 3-2
Cy 2015 Relative Value Units (Rvus) and Related Information Used In Determining Final Medicare Payments
CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSacea DRuGs
   Table 4-1
   Common Benzoyl Peroxide Formulations
   Table 4-2
   Common Retinoid Formulations
   Table 4-3
   Common Topical Antibiotic Formulations
   Table 4-3 (continued)
   Common Topical Antibiotic Formulations
   Table 4-3 (continued)
   Common Topical Antibiotic Formulations
   Table 4-4
   Common Oral Contraceptive Formulations
   Table 4-5
   Prescription Acne, Actinic Keratosis and Rosacea Formulations in Development
   Table 4-6
   The Worldwide Market for Prescription Acne and Rosacea Drugs by Type 2013-2020
   Figure 4-1
   The Worldwide Market for Prescription Acne and Rosacea Drugs Revenues by Type, 2013-2020
   Figure 4-2
   The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2015
   Figure 4-3
   The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2020
   Table 4-7
   Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
   Table 4-8
   Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
   Table 4-9
   The Worldwide Market for Prescription Antiacne and Rosacea Drugs by Geographical Region 2013-2020
   Figure 4-4
   The Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues by Geographical Region 2013-2020
   Figure 4-5
   The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2015
   Figure 4-6
   The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2020
   Table 4-10
Worldwide Market for Acne and Rosacea Drugs Market Share by Leading Supplier 2015

CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRuGs
   Table 5-1
   Common Prescription Keratolytic Formulations
   Table 5-2
Occlusive Moisturizers—Categories of Ingredients
   Table 5-3
   Common Prescription Moisturizers
   Table 5-4
   Common Prescription Retinoids for Antiaging and Photodamage
Table 5-5  
Common Prescription Sunscreens  
Table 5-6  
Other Prescription Antiaging and Photodamage Products  
Table 5-7  
Prescription Antiaging and Photodamage Formulations in Development  
Table 5-8  
The Worldwide Market Antiaging and Photodamage Drugs by Type 2013-2020  
Figure 5-1  
The Worldwide Market for Antiaging and Photodamage Drugs Revenues by Type 2013-2020  
Figure 5-2  
The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2015  
Figure 5-3  
The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2020  
Table 5-9  
Top Five EU Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015  
Table 5-10  
Top Four Rest of World Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015  
Table 5-11  
The Worldwide Market for Prescription Antiaging and Photodamage Drugs by Geographical Region 2013-2020  
Figure 5-4  
The Worldwide Market for Prescription Antiaging and Photodamage Drugs, Revenues by Geographical Region 2013-2020  
Figure 5-5  
The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2015  
Figure 5-6  
The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2020  
Table 5-12  
Worldwide Market for Prescription Antiaging and Photodamage Drugs Revenues and Market Share by Supplier 2015  
Figure 5-7  
Worldwide Market for Prescription Antiaging and Photodamage Drugs, Market Share by Leading Supplier 2015  
CHAPTER SIX:  
PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS  
Table 6-1  
Common Prescription Topical Corticosteroid Preparations  
Table 6-1 (continued)  
Common Prescription Topical Corticosteroid Preparations  
Table 6-2  
Common Prescription Systemic Corticosteroids  
Table 6-3  
Prescription Other Dermatitis Formulations  
Table 6-4  
Prescription Dermatitis Formulations in Development  
Table 6-5  
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Type 2013-2020  
Figure 6-1  
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Type 2013-2020  
Figure 6-2  
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2015  
Figure 6-3  
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2020  
Table 6-6  
Top Five EU Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)  
Table 6-7  
Top Four Rest of World Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
Table 6-8
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Geographical Region 2013-2020
Figure 6-4
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Geographical Region 2013-2020
Figure 6-5
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2015
Figure 6-6
The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2020
Table 6-9
Worldwide Market for Prescription Dermatitis and Seborrhea Drugs, Revenues and Market Share by Supplier 2015
Figure 6-7
Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Market Share by Leading Supplier 2015
CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS
Table 7-1
Common Prescription Systemic Antifungal Dermatological Formulations
Table 7-2
Common Prescription Topical Antifungal Dermatological Drugs
Table 7-3
Prescription Antifungal Dermatological Drugs in Development
Table 7-4
The Worldwide Market for Prescription Antifungal Dermatological Drugs by Type 2013-2020
Figure 7-1
The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Type 2013-2020
Figure 7-2
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2015
Figure 7-3
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2020
Table 7-5
Top Five EU Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
Table 7-6
Top Four Rest of World Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
Table 7-7
The Worldwide Market for Prescription Antifungal Dermatological Drugs by Geographical Region 2013-2020
Figure 7-4
The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Geographical Region 2013-2020
Figure 7-5
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2015
Figure 7-6
The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2020
Table 7-8
Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues and Market Share by Supplier 2015
Figure 7-7
Worldwide Market for Prescription Antifungal Dermatological Drugs Market Share by Leading Supplier 2015
CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS
Table 8-1
Common Prescription Hair Loss or Hair Removal Formulations
Table 8-2
Prescription Hair Loss or Hair Removal Formulations in Development
Table 8-3
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs by Type 2013-2020
Figure 8-1
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Type 2013-2020
Figure 8-2
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2015
Figure 8-3
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2020
Table 8-4
Top Five EU Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
Table 8-5
Top Four Rest of World Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
Table 8-6
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
Figure 8-4
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
Figure 8-5
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Geographical Region 2015
Figure 8-6
The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2020
Table 8-7
Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues and Market Share by Supplier 2015
Figure 8-7
Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Market Share by Leading Supplier 2015
CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS
Table 9-1
Common Prescription Hyperpigmentation/Melasma Formulations
Table 9-2
Common Prescription Depigmenting Agents
Table 9-3
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs by Type 2013-2020
Figure 9-1
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Revenues by Type 2013-2020
Figure 9-2
The Worldwide Market for Prescription Hyperpigmentation/ Melasma and Depigmenting Drugs, Share by Type 2015
Figure 9-3
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Share by Type 2020
Table 9-4
The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs by Geographical Region 2013-2020
Figure 9-4
The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs Revenues by Geographical Region 2013-2020
Figure 9-5
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2015
Figure 9-6
The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2020
CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS
Table 10-1
Selected Common Prescription Psoriasis Preparations
Selected Common Prescription Psoriasis Preparations
Table 10-2
Common Prescription Biologics for Psoriasis Treatment
Table 10-3
Prescription Psoriasis Preparations in Development
Table 10-3 (cont)
Prescription Psoriasis Preparations in Development
Table 10-4
The Worldwide Market for Prescription Psoriasis Drugs by Type 2013-2020 273
Figure 10-1
The Worldwide Market for Prescription Psoriasis Drugs Revenues by Type 2013-2020
Figure 10-2
The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2015 275
Figure 10-3
The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2020 276
Table 10-5
Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 10-6
Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 10-7
The Worldwide Market for Prescription Psoriasis Drugs by Geographical Region 2013-2020
Figure 10-4
The Worldwide Market for Prescription Psoriasis Drugs Revenues by Geographical Region 2013-2020
Figure 10-5
The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2015
Figure 10-6
The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2020
Table 10-8
Worldwide Market for Prescription Psoriasis Drugs Revenues and Market Share by Supplier 2015
Figure 10-7
Worldwide Market for Prescription Psoriasis Drugs Market Share by Leading Supplier 2015

CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS
Table 11-1
Malignant Conditions of the Skin
Table 11-2
Common Prescription Topical, Intralesional and Other Skin Cancer Agents . 296
Table 11-3
Prescription Skin Cancer Preparations in Development
Table 11-3 (continued)
Prescription Skin Cancer Preparations in Development
Table 11-4
The Worldwide Market for Skin Cancer Drugs 2013-2020
Figure 11-1
The Worldwide Market for Skin Cancer Drugs 2013-2020
Table 11-5
Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 11-6
Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
Table 11-7
The Worldwide Market for Prescription Skin Cancer Drugs by Geographical Region 2013-2020
Figure 11-2
The Worldwide Market for Prescription Skin Cancer Drugs Revenues by Geographical Region 2013-2020
Figure 11-3
The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2015
Figure 11-4
The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2020
Table 11-8
Worldwide Market for Prescription Skin Cancer Drugs Revenues and Market Share by Supplier 2015
Figure 11-5
Worldwide Market for Skin Cancer Drugs Market Share by Leading Supplier 2015

CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS
Table 12-1
Common Prescription Dermatological Systemic and Topical Antiviral Formulations
Table 12-2
Common Prescription Topical Antiparasitic Formulations
Table 12-3
Common Prescription Other Skin Formulations
Table 12-4
Prescription Miscellaneous Skin Preparations in Development
Table 12-5
The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Type 2013-2020

Figure 12-2
The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2015

Figure 12-3
The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2020

Table 12-6
Top Five EU Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015

Table 12-7
Top Four Rest of World Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015

Table 12-8
The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Geographical Region 2013-2020

Figure 12-4
The Worldwide Market for Prescription Miscellaneous Drugs Revenues by Geographical Region 2013-2020

Figure 12-5
The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2015

Figure 12-6
The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2020

CHAPTER THIRTEEN: WORLD MARKET SUMMARY

Table 13-1
The Worldwide Market for Prescription Dermatological Drugs, Revenues by Segment, 2013-2020

Figure 13-1
The Worldwide Market for Prescription Dermatological Drugs Revenues by Dermatological Segment 2013-2020

Figure 13-2
The Worldwide Market for Dermatological Drugs Market Share by Type 2015

Figure 13-3
The Worldwide Market for Dermatological Drugs Market Share by Type 2020

Table 13-2
Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015

Figure 13-4
Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015

Figure 13-5
Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2020

Table 13-3
Worldwide Market for Prescription Dermatological Drugs Segments of Major Participation by Manufacturer 2015

Table 13-4
Worldwide Market for Prescription Dermatological Drug Revenues and Market Share by Supplier 2015

LIST OF COMPANIES

Ordering:

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3398429/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4200</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 8400</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World